• nkat2112@sh.itjust.works
    link
    fedilink
    English
    arrow-up
    45
    ·
    5 months ago

    In a study presented at the 25th international Aids conference in Munich on Tuesday, experts calculated that the minimum price for mass production of a generic version, based on the costs of lenacapavir’s ingredients and manufacturing, and allowing for 30% profit, was $40 a year , assuming 10 million people used it annually. In the long-term, 60 million people would probably need to take the drug preventatively to lower HIV levels significantly, they said.

    Accounting for 30% profit seems reasonable to me.

    Yet they’re selling it for 1000x the price.

    I understand they need to recoup research costs, but…

    I have no other words.

    • NovaPrime@lemmy.ml
      link
      fedilink
      arrow-up
      10
      ·
      5 months ago

      The research cost recovery line they often yap about is bullshit itself though. The overwhelming majority of pharma research like the one involved here is subsidized through taxpayer dollars already, and they get tax incentives and write offs for failed research. If we had a sane, working government we could nationalize all life saving medications funded by public money while still allowing the inventors to enjoy some (reasonable) economic benefits from the research